JP2009539994A - 癌の治療のための化合物及び組成物 - Google Patents

癌の治療のための化合物及び組成物 Download PDF

Info

Publication number
JP2009539994A
JP2009539994A JP2009515473A JP2009515473A JP2009539994A JP 2009539994 A JP2009539994 A JP 2009539994A JP 2009515473 A JP2009515473 A JP 2009515473A JP 2009515473 A JP2009515473 A JP 2009515473A JP 2009539994 A JP2009539994 A JP 2009539994A
Authority
JP
Japan
Prior art keywords
composition
dose
cancer
mammal
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539994A5 (https=
Inventor
シー． アデルマン ダニエル
ジェイ． エバンチク マルク
スドハカル アナントハ
ウィルリアム ジャコブス ジェフフレイ
エー．シルべルマン ジェフフレイ
Original Assignee
サネシス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009539994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サネシス ファーマシューティカルズ， インコーポレイテッド filed Critical サネシス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2009539994A publication Critical patent/JP2009539994A/ja
Publication of JP2009539994A5 publication Critical patent/JP2009539994A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009515473A 2006-06-12 2007-06-12 癌の治療のための化合物及び組成物 Pending JP2009539994A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81283506P 2006-06-12 2006-06-12
PCT/US2007/013873 WO2007146335A2 (en) 2006-06-12 2007-06-12 Compounds and compositions for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013105196A Division JP2013209398A (ja) 2006-06-12 2013-05-17 癌の治療のための化合物及び組成物

Publications (2)

Publication Number Publication Date
JP2009539994A true JP2009539994A (ja) 2009-11-19
JP2009539994A5 JP2009539994A5 (https=) 2010-07-29

Family

ID=38832517

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009515473A Pending JP2009539994A (ja) 2006-06-12 2007-06-12 癌の治療のための化合物及び組成物
JP2013105196A Pending JP2013209398A (ja) 2006-06-12 2013-05-17 癌の治療のための化合物及び組成物
JP2015237527A Pending JP2016094434A (ja) 2006-06-12 2015-12-04 癌の治療のための化合物及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013105196A Pending JP2013209398A (ja) 2006-06-12 2013-05-17 癌の治療のための化合物及び組成物
JP2015237527A Pending JP2016094434A (ja) 2006-06-12 2015-12-04 癌の治療のための化合物及び組成物

Country Status (11)

Country Link
US (4) US8124773B2 (https=)
EP (2) EP2354138A1 (https=)
JP (3) JP2009539994A (https=)
KR (1) KR20090021215A (https=)
CN (2) CN101505753B (https=)
AU (1) AU2007258280B2 (https=)
BR (1) BRPI0713637A2 (https=)
CA (1) CA2654876A1 (https=)
IL (2) IL195883A0 (https=)
MX (1) MX2008015775A (https=)
WO (1) WO2007146335A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013209398A (ja) * 2006-06-12 2013-10-10 Sunesis Pharmaceuticals Inc 癌の治療のための化合物及び組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559652C (en) 2004-03-15 2017-02-14 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 in treating cancer
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2214662B1 (en) * 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en) 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) * 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
WO2010099526A1 (en) 2009-02-27 2010-09-02 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
AU2013202641B2 (en) * 2009-09-04 2015-07-23 Sunesis Pharmaceuticals, Inc. Stable sns-595 compositions and methods of preparation
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034559A1 (en) * 1994-06-14 1995-12-21 Dainippon Pharmaceutical Co., Ltd. Novel compound, process for producing the same, and antitumor agent
JPH09221424A (ja) * 1995-12-13 1997-08-26 Dainippon Pharmaceut Co Ltd 抗腫瘍剤
US20050203120A1 (en) * 2004-03-15 2005-09-15 Adelman Daniel C. SNS-595 and methods of using the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5078966A (en) 1990-08-14 1992-01-07 Nalco Chemical Company Carbohydrazide to prevent hydrogen blistering and corrosion of metal surfaces in contact with refinery overhead condensates
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
CA2277481A1 (en) 1997-01-13 1998-07-16 Kudos Pharmaceuticals Limited Assays, agents, therapy and diagnosis relating to modulation of cellular dna repair activity
US20020032216A1 (en) 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
US6291643B1 (en) 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
US6171857B1 (en) 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
MXPA01008626A (es) 1999-02-26 2002-04-24 Univ Johns Hopkins Inhibidor novedoso de muerte programada de celula.
US6670144B1 (en) 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6479541B1 (en) 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
AU2001296558A1 (en) 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2002228772B2 (en) 2000-11-02 2005-12-08 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
US20030016887A1 (en) * 2001-07-18 2003-01-23 Fu-Long Su Receiving bag with seal opening and sealing clip
WO2004085418A2 (en) 2003-03-24 2004-10-07 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as dna-pk inhibitors
US7387499B2 (en) 2004-08-13 2008-06-17 Gateway Inc. System and method for testing the operation of a cooling fan
KR20080041298A (ko) 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
AU2007258280B2 (en) * 2006-06-12 2013-05-02 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
US20100048609A1 (en) 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
EP2214662B1 (en) 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en) 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034559A1 (en) * 1994-06-14 1995-12-21 Dainippon Pharmaceutical Co., Ltd. Novel compound, process for producing the same, and antitumor agent
JPH09221424A (ja) * 1995-12-13 1997-08-26 Dainippon Pharmaceut Co Ltd 抗腫瘍剤
US20050203120A1 (en) * 2004-03-15 2005-09-15 Adelman Daniel C. SNS-595 and methods of using the same

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN5009011464; ＨＯＣＨ，Ｕ．，ＥＴ　ＡＬ．: '"ＣＹＰ４５０　Ｉｎｈｉｂｉｔｉｏｎ，Ｉｎｄｕｃｔｉｏｎ，Ｍｅｔａｂｏｌｉｓｍ，ａｎｄ　Ｒｏｕｔｅｓ　ｏｆ　Ｅｌｉｍｉｎａｔｉｏｎ　ｏｆ　ＳＮＳ-５９５，ａ　Ｎｏｖｅｌ　Ｃｅｌｌ　Ｃｙｃｌｅ' ＡＡＣＲ-ＮＣＩ-ＥＯＲＴＣ　ｉｎｔｅｒｎａｔｉｏｎａｌ，　Ｐｏｓｔｅｒ　Ｓｅｓｓｉｏｎ　Ｃ , 20051117 *
JPN5009011465; ＥＢＢＩＮＧＨＡＵＳ，Ｓ．，ＥＴ　ＡＬ．: '"Ａ　Ｐｈａｓｅ　Ｉ　ｔｒｉａｌ　ｏｆ　ｗｅｅｋｌｙ　ＳＮＳ-５９５　ｉｎ　ｐａｔｉｅｎｔｓ　（ＰＴＳ）　ｗｉｔｈ　ｒｅｆｒａｃｔｏｒｙ　ｃａｎｃｅｒ"' ＰＲＯＣＥＥＤＩＮＧＳ　ＯＦ　ＴＨＥ　ＡＮＮＵＡＬ　ＭＥＥＴＩＮＧＳ　ＯＦ　ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ ＶＯＬ．４７, 20060401, Ｐ．６８５，＃２９１３ *
JPN5009011466; ＨＵＲＷＩＴＺ，Ｈ．，ＥＴ　ＡＬ．: '"ＳＮＳ-５９５　ｄｅｍｏｎｓｔｒａｔｅｓ　Ｃｌｉｎｉｃａｌ　Ａｃｔｉｖｉｔｙ　ａｎｄ　Ｄｏｓｅ　Ｐｒｏｐｏｒｔｉｏｎａｌ　Ｐｈａｒｍａｃｏｋｉｎｅｔｉｃｓ　（ＰＫ）　ｉｎ　Ｔｗｏ　Ｐｈａｓｅ　１　Ｃ' ＡＳＣＯ　Ａｎｎｕａｌ　Ｍｅｅｔｉｎｇ，Ｇｅｏｒｇｉａ　Ｗｏｒｌｄ　Ｃｏｎｇｒｅｓｓ　Ｃｅｎｔｅｒ，Ａｔｌａｎｔａ，Ｇｅｏｒｇｉａ Ａｂｓｔｒａｃｔ　Ｎｕｍｂｅｒ：　３０６２, 20060604 *
JPN5009011467; ＴＳＵＺＵＫＩ，Ｙ．，ＥＴ　ＡＬ．: '"Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　Ｓｔｒｕｃｔｕｒｅ-Ａｃｔｉｖｉｔｙ　Ｒｅｌａｔｉｏｎｓｈｉｐｓ　ｏｆ　Ｎｏｖｅｌ　７-Ｓｕｂｓｔｉｔｕｔｅｄ　１，４-Ｄｉｈｙｄｒｏ-４-ｏｘｏ-１-（２-ｔｈｉａｚｏ' ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ ＶＯＬ．４７，ＮＯ．８, 20040101, ＰＰ．２０９７-２１０９ *
JPN6012056530; ＴＳＵＺＵＫＩ，Ｙ．，ＥＴ　ＡＬ．: '"Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ｓｔｒｕｃｔｕｒｅ-ａｃｔｉｖｉｔｙ　ｒｅｌａｔｉｏｎｓｈｉｐｓ　ｏｆ　ｎｏｖｅｌ　７-ｓｕｂｓｔｉｔｕｔｅｄ　１，４-ｄｉｈｙｄｒｏ-４-ｏｘｏ-１-（２-ｔｈｉａｚｏ' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ ＶＯＬ．１４，ＮＯ．１２, 20040621, ＰＰ．３１８９-３１９３ *
JPN6012056532; ＴＳＵＺＵＫＩ，Ｙ．，ＥＴ　ＡＬ．: '"Ｐｒａｃｔｉｃａｌ　ｓｙｎｔｈｅｓｉｓ　ｏｆ　（３Ｓ，４Ｓ）-３-ｍｅｔｈｏｘｙ-４-ｍｅｔｈｙｌａｍｉｎｏｐｙｒｒｏｌｉｄｉｎｅ"' ＴＥＴＲＡＨＥＤＲＯＮ　ＡＳＹＭＭＥＴＲＹ ＶＯＬ．１２，ＮＯ．２１, 20011126, ＰＰ．２９８９-２９９７ *
JPN6012056533; ＴＳＵＺＵＫＩ，Ｙ．，ＥＴ　ＡＬ．: '"Ｅｆｆｉｃｉｅｎｔ　ｓｔｅｒｅｏｓｐｅｃｉｆｉｃ　ｓｙｎｔｈｅｓｉｓ　ｏｆ　（Ｓ，Ｓ）-３-ｍｅｔｈｏｘｙ-４-ｍｅｔｈｙｌａｍｉｎｏｐｙｒｒｏｌｉｄｉｎｅ"' ＴＥＴＲＡＨＥＤＲＯＮ　ＡＳＹＭＭＥＴＲＹ ＶＯＬ．１２，ＮＯ．１２, 20010716, ＰＰ．１７９３-１７９９ *
JPN6012056535; ＣＨＩＢＡ，Ｋ．，ＥＴ　ＡＬ．: '"ＰＲＡＣＴＩＣＡＬ　ＳＹＮＴＨＥＳＩＳ　ＯＦ　ＡＧ-７３５２，　ＡＮ　ＯＰＴＩＣＡＬＬＹ　ＡＣＴＩＶＥ　ＮＥＷ　ＡＮＴＩＴＵＭＯＲ　ＡＧＥＮＴ"' ＢＯＯＫ　ＯＦ　ＡＢＳＴＲＡＣＴＳ　２１８ＴＨ　ＡＭＥＲＩＣＡＮ　ＣＨＥＭＩＣＡＬ　ＳＯＣＩＥＴＹ　（ＡＣＳ）　ＮＡＴＩＯＮＡＬ　ＭＥＥＴＩＮＧ　ＡＵＧＵＳＴ　２２-２６，１９９９ , 19990101, Ｐ．３，ｐａｒａｇｒａｐｈ　１２７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013209398A (ja) * 2006-06-12 2013-10-10 Sunesis Pharmaceuticals Inc 癌の治療のための化合物及び組成物

Also Published As

Publication number Publication date
US8124773B2 (en) 2012-02-28
JP2016094434A (ja) 2016-05-26
CA2654876A1 (en) 2007-12-21
US20170101404A1 (en) 2017-04-13
EP2354138A1 (en) 2011-08-10
US20150150858A1 (en) 2015-06-04
CN101505753B (zh) 2014-05-21
WO2007146335A2 (en) 2007-12-21
US20100029708A1 (en) 2010-02-04
EP2043645A2 (en) 2009-04-08
MX2008015775A (es) 2009-04-17
IL243294A0 (en) 2016-02-29
JP2013209398A (ja) 2013-10-10
US9676774B2 (en) 2017-06-13
US20120245198A1 (en) 2012-09-27
KR20090021215A (ko) 2009-02-27
AU2007258280B2 (en) 2013-05-02
AU2007258280A1 (en) 2007-12-21
IL195883A0 (en) 2009-09-01
WO2007146335A3 (en) 2009-02-12
CN104027333B (zh) 2017-05-17
CN101505753A (zh) 2009-08-12
US8765954B2 (en) 2014-07-01
BRPI0713637A2 (pt) 2012-10-23
CN104027333A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
JP2016094434A (ja) 癌の治療のための化合物及び組成物
US9724338B2 (en) Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US20180098975A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US20200002316A1 (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
EP1931339B1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20180088401A (ko) 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법
CA2620915C (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2013219242B2 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CN104873502A (zh) 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
AU2016210657A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130730